|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
Abdominal or stomach pain |
|
skin rash |
|
Belching |
|
bone pain |
|
colitis |
|
Iritis, acute |
|
Arthralgia |
|
diarrhea |
|
headache |
|
Amblyopia |
|
asthenia |
|
bronchitis |
|
chest pain |
|
constipation |
|
dizziness |
|
dry eyes |
|
flu-like syndrome |
|
leg cramps |
|
myasthenia |
|
nausea |
|
peripheral edema |
|
sinusitis |
|
tinnitus |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Gastrointestinal disorders, upper |
|
>> Renal function impairment |
|
|
ADULT DOSE:
|
|
Glucocorticoid-induced osteoporosis (prophylaxis),
Glucocorticoid-induced osteoporosis (treatment),
Postmenopausal osteoporosis (prophylaxis), and
Postmenopausal osteoporosis (treatment)-
Oral, 5 mg daily at least thirty minutes before the first food or drink of the day other than water .
Paget's disease of bone (treatment) -
Oral, 30 mg once a day for two months .
Re-treatment may be considered, after a posttreatment observation period of at least two months, if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase values .
For retreatment, the dose and duration of therapy are the same as for initial treatment . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy in children younger than 18 years of age have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|